A single-dose, open-label, three-way crossover study, to assess the effect of pre-dose meal composition on the pharmacokinetics of gastro-retentive AP-DLD 50/500mg

Trial Profile

A single-dose, open-label, three-way crossover study, to assess the effect of pre-dose meal composition on the pharmacokinetics of gastro-retentive AP-DLD 50/500mg

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2015

At a glance

  • Drugs Levodopa/carbidopa (Primary)
  • Indications Parkinson's disease
  • Focus Pharmacokinetics
  • Most Recent Events

    • 14 Oct 2015 New trial record
    • 12 Oct 2015 Results published in an Intec Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top